Systemic therapies for unresectable locoregional melanoma: a significant area of need

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Metastatic melanoma management has been revolutionized by immune checkpoint inhibitors and BRAF-MEK inhibitors.
• Unresectable stage III melanoma presents unique treatment challenges with limited evidence for advanced systemic therapies.
• The definition of unresectable disease is evolving due to the efficacy of new systemic treatments.

Purpose of the Study:

• To review the current evidence and discuss the role of systemic therapies in unresectable stage III melanoma.
• To address the need for guidance on incorporating novel therapies into treatment paradigms for this patient group.
• To explore the implications of effective systemic therapies on the definition and management of unresectable disease.

Main Methods:

• Literature review of studies on systemic therapies for metastatic melanoma.
• Analysis of current treatment guidelines and expert opinions.
• Discussion of clinical trial data and real-world evidence for unresectable stage III disease.

Main Results:

• Immune checkpoint inhibitors and BRAF-MEK inhibitors show promise but lack robust evidence in unresectable stage III melanoma.
• Patients with unresectable stage III disease face significant morbidity from both the condition and local treatments.
• Progression to distant metastases is a concern even with systemic therapy use in this stage.

Conclusions:

• Further clinical evidence is required to establish the definitive benefit of systemic therapies in unresectable stage III melanoma.
• The evolving landscape of melanoma treatment necessitates a re-evaluation of treatment strategies for stage III disease.
• Optimizing the use of novel systemic agents is crucial for improving outcomes in patients with unresectable stage III melanoma.